Safety and Immunogenicity Study of the Recombinant Hepatitis E Vaccine(Escherichia Coli) in Healthy Volunteers Aged Over 65 Years

Trial Profile

Safety and Immunogenicity Study of the Recombinant Hepatitis E Vaccine(Escherichia Coli) in Healthy Volunteers Aged Over 65 Years

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 May 2016

At a glance

  • Drugs Recombinant hepatitis E vaccine (Hecolin) (Primary)
  • Indications Hepatitis E
  • Focus Adverse reactions
  • Sponsors Xiamen Innovax Biotech
  • Most Recent Events

    • 05 May 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 17 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top